Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C
Authors
Keywords
-
Journal
Expert Opinion on Drug Metabolism & Toxicology
Volume 14, Issue 6, Pages 649-657
Publisher
Informa UK Limited
Online
2018-06-01
DOI
10.1080/17425255.2018.1483336
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis
- (2018) Ali Mahmoud Ahmed et al. JOURNAL OF MEDICAL VIROLOGY
- Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection
- (2018) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection
- (2018) Ulrich Spengler PHARMACOLOGY & THERAPEUTICS
- Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications
- (2017) Pierre Nahon et al. GASTROENTEROLOGY
- Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus
- (2017) Eric Lawitz et al. HEPATOLOGY
- Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1
- (2017) Jia-Horng Kao et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis
- (2017) Paul Y. Kwo et al. JOURNAL OF HEPATOLOGY
- EASL Recommendations on Treatment of Hepatitis C 2016
- (2017) JOURNAL OF HEPATOLOGY
- The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings
- (2017) Hitomi Sezaki et al. LIVER INTERNATIONAL
- Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions
- (2017) Steven W. Johnson et al. Current Infectious Disease Reports
- Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis
- (2016) A. Majumdar et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Hepatitis C virus resistance to the new direct-acting antivirals
- (2016) Isabella Esposito et al. Expert Opinion on Drug Metabolism & Toxicology
- Prevention and management of treatment failure to new oral hepatitis C drugs
- (2016) Laura Benítez-Gutiérrez et al. EXPERT OPINION ON PHARMACOTHERAPY
- Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
- (2016) Paul Kwo et al. HEPATOLOGY
- Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)
- (2016) Eric Lawitz et al. HEPATOLOGY
- Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection
- (2016) Joji Toyota et al. JOURNAL OF GASTROENTEROLOGY
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
- (2016) Christoph Sarrazin JOURNAL OF HEPATOLOGY
- Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection
- (2015) Stefan Zeuzem et al. ANNALS OF INTERNAL MEDICINE
- Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug–Drug Interactions
- (2015) Timothy Eley et al. CLINICAL PHARMACOKINETICS
- Daclatasvir: A Review of Its Use in Adult Patients with Chronic Hepatitis C Virus Infection
- (2015) Paul L. McCormack DRUGS
- Asunaprevir for hepatitis C: a safety evaluation
- (2015) Ivan Gentile et al. Expert Opinion On Drug Safety
- Beclabuvir for the treatment of hepatitis C
- (2015) Ivan Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Daclatasvir for the treatment of chronic hepatitis C
- (2015) Elisabetta Degasperi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Asunaprevir (BMS-650032) for the treatment of hepatitis C virus
- (2015) Nobuhisa Akamatsu et al. Expert Review of Anti-Infective Therapy
- Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection
- (2015) Sheng-Shun Yang et al. Hepatology International
- Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
- (2015) Andrew J. Muir et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
- (2015) Fred Poordad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients
- (2015) Hiromitsu Kumada et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- A pill a day keeps HCV away
- (2015) Ivan Gentile et al. LANCET INFECTIOUS DISEASES
- Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients
- (2015) Gregory T. Everson et al. LIVER INTERNATIONAL
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
- (2015) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1
- (2015) David L. Wyles et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization of ADME properties of [14C]asunaprevir (BMS-650032) in humans
- (2015) Jiachang Gong et al. XENOBIOTICA
- Organic Anion Transporting Polypeptide-Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease
- (2015) T Eley et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides
- (2014) Tomomi Furihata et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection
- (2014) Karen D. Sims et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase
- (2014) Julie A. Lemm et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
- (2014) Ivan Gentile et al. Expert Review of Anti-Infective Therapy
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
- (2014) Hiromitsu Kumada et al. HEPATOLOGY
- Mechanism of Inhibition for BMS-791325, a Novel Non-nucleoside Inhibitor of Hepatitis C Virus NS5B Polymerase
- (2014) Karen L. Rigat et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
- (2014) Paul M. Scola et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase
- (2014) Robert G. Gentles et al. JOURNAL OF MEDICINAL CHEMISTRY
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
- (2014) Michael Manns et al. LANCET
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Network meta-analysis of direct-acting antivirals in combination with peginterferon–ribavirin for previously untreated patients with hepatitis C genotype 1 infection
- (2014) E. Druyts et al. QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
- Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
- (2013) Gregory T. Everson et al. GASTROENTEROLOGY
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
- (2013) J. Guedj et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
- (2012) Fiona McPhee et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir
- (2012) Lenore A. Pelosi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Combinations of Lambda Interferon with Direct-Acting Antiviral Agents Are Highly Efficient in Suppressing Hepatitis C Virus Replication
- (2012) Jacques Friborg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
- (2011) Richard E. Nettles et al. HEPATOLOGY
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changing Trends in Hepatitis C Infection over the Past 50 Years in Japan
- (2010) Hobyung Chung et al. INTERVIROLOGY
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- New Therapies for Hepatitis C Virus Infection
- (2009) Vincent Soriano et al. CLINICAL INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now